Niagen Bioscience, Inc. (NAGE)
Official siteCONSUMER DEFENSIVE • BIOTECHNOLOGY • NASDAQ
Market Cap: $159.19M
Last updated: Nov 17, 2026 at 4:16 PM ET
Niagen Bioscience, Inc. (NAGE) Stock Chart
Niagen Bioscience (NAGE) has a latest price of $2.04 on Nov 17, 2026, 71.3% below its 52-week high of $7.12. Its price fell 70.3% over the past 12 months. The month-end price fell 15.6% over the 10 years through Oct 2026, a compound annual decline of 1.7%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $14.41 in Jun 2025 and its lowest $1.23 in Sep 2022, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart NAGE with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for NAGE.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 35.6%, and over 6 months it fell 44.4%. The month-end price rose 76.5% over the 3 years through Oct 2026, a compound annual rate of 20.9%.
| Period | Change |
|---|---|
| 1 month | -18.4% |
| 3 months | -35.6% |
| 6 months | -44.4% |
| 12 months | -70.3% |
| 12 months, with dividends | -70.3% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +76.5% | +20.9% |
| 5 years | -62.4% | -17.8% |
| 10 years | -15.6% | -1.7% |
Price by Year
Its best calendar year was 2024, when the price rose 271.0%, and its weakest was 2022, when it fell 55.1%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $2.33 | -63.4% |
| 2025 | $6.36 | +19.9% |
| 2024 | $5.30 | +271.0% |
| 2023 | $1.43 | -14.9% |
| 2022 | $1.68 | -55.1% |
| 2021 | $3.74 | -22.1% |
| 2020 | $4.80 | +11.4% |
| 2019 | $4.31 | +25.7% |
| 2018 | $3.43 | -41.7% |
| 2017 | $5.88 | +77.6% |
Trading Range
The price is 22.1% below its 50-day average of $2.62 and 44.6% below its 200-day average of $3.68.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $2.04 | |
| 52-week high | $7.12 | -71.3% |
| 52-week low | $1.97 | +3.6% |
| 50-day average | $2.62 | -22.1% |
| 200-day average | $3.68 | -44.6% |
Price Risk
Over 3 years, its largest fall from a peak was 86.1%.
| Measure | Value |
|---|---|
| 1-year beta | 1.69 |
| Largest fall, 1 year | -71.4% |
| Largest fall, 3 years | -86.1% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About NAGE
What is NAGE's 1-year price change?
Niagen Bioscience's price fell 70.3% over the past 12 months. With dividends included, the 12-month total return was -70.3%.
What is NAGE's 5-year price change?
Niagen Bioscience's month-end price fell 62.4% over the 5 years through Oct 2026, a compound annual decline of 17.8%. These figures leave out dividends.
What is NAGE's 52-week high and low?
Niagen Bioscience's 52-week high is $7.12 and its 52-week low is $1.97. Its latest price of $2.04 on Nov 17, 2026 is 71.3% below the high.
What is NAGE's beta?
Niagen Bioscience's 1-year beta against the S&P 500 is 1.69, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 71.4%.
Is the NAGE chart free?
Yes. Advanced Charting for NAGE is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
NAGE pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors